Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

NLS Pharmaceutics And Kadimastem Enter Binding Term Sheet For Transaction Under Which Kadimastem will Become A Wholly Owned Subsidiary Of NLS; Kadimastem's Shareholders To Hold 85% Of Issued And Outstanding Shares Of Merged Company

Author: Benzinga Newsdesk | July 29, 2024 07:08am

Posted In: NLSP

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist